Companies G1 Therapeutics
G1 Therapeutics (GTHX): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
G1 Therapeutics no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers31st pct.Of 18 peer CEOs
CEO pay, last three years
- $3,015,980FY2022
- $3,250,658FY2023
CEO total pay was $3,250,658 in fiscal 2023, up from $3,015,980 in fiscal 2022.
FY2023: salary $794,976 · bonus $0 · stock awards $1,392,022 · option awards $666,209
Frequently asked questions
Who was the highest-paid executive at G1 Therapeutics in fiscal 2023?
As disclosed, John Bailey (Chief Executive Officer and President) was the highest-paid executive at G1 Therapeutics in fiscal 2023, with total compensation of $3,250,658.
How does G1 Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, John Bailey's total compensation ranked at the 31st percentile of G1 Therapeutics's disclosed peer group.
What is G1 Therapeutics's CEO-to-median employee pay ratio?
As disclosed, G1 Therapeutics's CEO-to-median employee pay ratio was 12:1.
How did shareholders vote on G1 Therapeutics's executive compensation?
As disclosed, 84% of shareholders supported G1 Therapeutics's executive compensation in the latest say-on-pay vote.
How much does G1 Therapeutics spend in total on board compensation for fiscal 2023?
As disclosed, G1 Therapeutics reported total board compensation of $816,050 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Bailey | $794,976 | $0 | $1,392,022 | $666,209 | $387,551 | $0 | $9,900 | $3,250,658 |
| Chief Executive Officer and President | ||||||||
| Mark Avagliano | 483,604 | 0 | 338,276 | 169,533 | 170,229 | 0 | 9,900 | 1,171,543 |
| Chief Business Officer | ||||||||
| Rajesh Malik | 480,343 | 0 | 307,334 | 147,262 | 163,317 | 0 | 9,900 | 1,108,156 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| John Bailey | $3,250,658 | $3,015,980 | — | ↑ +234,678 |
| Mark Avagliano | 1,171,543 | 1,137,024 | — | ↑ +34,519 |
| Rajesh Malik | 1,108,156 | 1,121,497 | — | ↓ −13,341 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation philosophy focuses on aligning pay and performance to motivate, attract, and retain a highly skilled team of executives while aligning their long-term interests with those of stockholders. The program targets base salaries and total direct compensation at the 50th percentile of the peer group market, with a significant portion of compensation being variable and tied to long-term stock performance through equity grants.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, Aon’s Human Capital Solutions Practice |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Avagliano | Option | 2,500 | 21.08 | — |
| Rajesh Malik | Option | 2,500 | 21.08 | — |
| Mark Avagliano | RSU | 4,125 | — | 12,581 |
| Rajesh Malik | RSU | 4,125 | — | 12,581 |
| Mark Avagliano | RSU | 7,500 | — | 22,875 |
| Rajesh Malik | RSU | 7,500 | — | 22,875 |
| Mark Avagliano | Option | 15,716 | 18.07 | — |
| Rajesh Malik | Option | 15,716 | 18.07 | — |
| Rajesh Malik | RSU | 17,900 | — | 54,595 |
| Rajesh Malik | PSU | 17,900 | — | 54,595 |
| Mark Avagliano | RSU | 20,600 | — | 62,830 |
| Mark Avagliano | PSU | 20,600 | — | 62,830 |
| Mark Avagliano | Option | 27,606 | 10.69 | — |
| Rajesh Malik | Option | 27,606 | 10.69 | — |
| Rajesh Malik | RSU | 28,600 | — | 0 |
| John Bailey | RSU | 28,750 | — | 87,688 |
| Mark Avagliano | RSU | 35,000 | — | 106,750 |
| Rajesh Malik | RSU | 35,000 | — | 106,750 |
| Rajesh Malik | Option | 35,700 | 5.73 | — |
| Mark Avagliano | Option | 41,100 | 5.73 | — |
| John Bailey | RSU | 71,111 | — | 216,889 |
| John Bailey | RSU | 80,700 | — | 246,135 |
| John Bailey | PSU | 80,700 | — | 246,135 |
| John Bailey | Option | 106,250 | 10.69 | — |
| John Bailey | RSU | 160,000 | — | 488,000 |
| John Bailey | Option | 161,300 | 5.73 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mark A. Velleca, M.D., Ph.DNot independent · Not standing for re-election · Departed during FY | $33,750 | $0 | $0 | — | $200,000 | $233,750 |
| Garry A. NicholsonIndependent · Board Chair · Nominating and Governance (Chair) · Audit | 105,000 | 28,300 | 62,054 | — | 0 | 195,354 |
| Glenn P. MuirIndependent · Compensation · Audit (Chair) | 82,500 | 28,300 | 62,054 | — | 0 | 172,854 |
| Cynthia L. FlowersIndependent · Compensation · Nominating and Governance | 72,500 | 28,300 | 62,054 | — | 0 | 162,854 |
| Jacks LeeIndependent · Audit | 55,000 | 28,300 | 62,054 | — | 0 | 145,354 |
| Alicia SecorIndependent · Compensation | 52,500 | 28,300 | 62,054 | — | 0 | 142,854 |
| Norman E. Sharpless, M.DIndependent | 45,000 | 28,300 | 62,054 | — | 0 | 135,354 |
| John E. Bailey JrEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $375,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $3 |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $446,250 |
| Equity awards (grant-date value) | $169,800 |
| All other compensation | $200,000 |
| Total cost of the board | $816,050 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names G1 Therapeutics as a peer
Companies that benchmark against GTHX
5 companies name GTHX as a compensation peer
The list of companies that name GTHX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ANAB AnaptysBio, Inc.TGTX TG Therapeutics, Inc.MGNX MacroGenics, Inc.DCPH Deciphera Pharmaceuticals, Inc.RCUS Arcus Biosciences, Inc.YMAB Y-mAbs Therapeutics, Inc.KPTI Karyopharm Therapeutics Inc. Atara Biotheraputics, Inc.RIGL Rigel Pharmaceuticals, Inc.LXRX Reata Pharmaceuticals, Inc.BYSI BeyondSpring Inc.URGN UroGen Pharma, Inc.ESPR Esperion Therapeutics, Inc.AGEN Agenus Inc.IOVA Iovance Biotherapeutics, Inc.MRNS AVEO Pharmaceuticals, Inc.RYTM Rhythm Pharmaceuticals, Inc.IMGN ImmunoGen Inc.
Peer reciprocity
The companies G1 Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics, Inc. | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 3 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 4 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 5 | Deciphera Pharmaceuticals, Inc. | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 6 | ImmunoGen Inc. | 2022 | Mark Enyedy | 759,490 | — | 4,137,596 | 515,213 | 5,422,421 |
| 7 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 8 | Y-mAbs Therapeutics, Inc. | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 9 | UroGen Pharma, Inc. | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 10 | Reata Pharmaceuticals, Inc. | 2025 | Michael Exton | 650,576 | 1,049,304 | 1,355,231 | 0 | 3,553,953 |
| 11 | Esperion Therapeutics, Inc. | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 12 | G1 Therapeutics | 2023 | John Bailey | 794,976 | 1,392,022 | 666,209 | 387,551 | 3,250,658 |
| 13 | Aveo Pharmaceuticals, Inc. | 2023 | Scott Braunstein | 650,000 | 475,200 | 1,728,000 | 351,000 | 3,214,100 |
| 14 | Karyopharm Therapeutics Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 15 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 16 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
| 17 | Agenus Inc. | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
| 18 | BeyondSpring Inc. | 2025 | Lan Huang | 452,920 | 0 | 37,522 | 201,323 | 702,182 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| G1 Therapeutics | not disclosed | not disclosed | not disclosed | Radford, Aon’s Human Capital Solutions Practice |
| Agenus Inc. | 125% | Options 100 | not disclosed | Aon Radford |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Aveo Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| BeyondSpring Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Deciphera Pharmaceuticals, Inc. | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| Esperion Therapeutics, Inc. | 110% | not disclosed | not disclosed | not disclosed |
| ImmunoGen Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Karyopharm Therapeutics Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Reata Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| TG Therapeutics, Inc. | 131% | RSU 100 | No | Compensia, Inc. |
| UroGen Pharma, Inc. | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Y-mAbs Therapeutics, Inc. | 85.6% | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-13 | 16,706,545 | 3,182,510 | 92,563 | 84% | Passed |
| 2023 | 2023-06-15 | 14,070,123 | 2,379,219 | 4,400,763 | 85.54% | Passed |
| 2022 | 2022-06-23 | 11,555,526 | 3,814,714 | 1,454,698 | 75.18% | Passed |
| 2021 | 2021-06-17 | 19,692,679 | 545,659 | 54,264 | 97.3% | Passed |
| 2020 | 2020-06-11 | 24,148,423 | 954,778 | 3,012,963 | 96.2% | Passed |
| 2019 | 2019-06-12 | 25,786,488 | 2,061,915 | 4,655 | 92.6% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-13 | 84%a |
| 2023 | 2023-06-15 | 85.54%b |
| 2022 | 2022-06-23 | 75.18%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
b. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 12 : 1 |
|---|---|
| CEO total compensation | $3,250,658 |
| Median employee compensation | $281,293 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Andrew Perry | Chief Commercial Officer | 2024-05-13 | D | 8,151 | $5 | $39,034 | Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-05-13 | D | 8,151 | 5 | 39,034 | Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-05-13 | D | 8,151 | 5 | 39,034 | Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-05-13 | D | 8,151 | 5 | 39,034 | Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-05-13 | D | 8,151 | 5 | 39,034 | Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-05-13 | D | 37,258 | 5 | 178,421 | Common | Form 4 ↗ |
| Monica R. Thomas | Chief Legal & People Officer | 2024-05-23 | D | 5,826 | 4 | 24,864 | Common | Form 4 ↗ |
| Jacks Lee | Director | 2024-06-13 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-06-13 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry A. Nicholson | Director | 2024-06-13 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry A. Nicholson | Director | 2024-06-13 | A | 10,000 | 0 | 0 | RSU | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-06-13 | A | 10,000 | 0 | 0 | RSU | Form 4 ↗ |
| Jacks Lee | Director | 2024-06-13 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Alicia Secor | Director | 2024-06-13 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norman Sharpless | Director | 2024-06-13 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norman Sharpless | Director | 2024-06-13 | A | 10,000 | 0 | 0 | RSU | Form 4 ↗ |
| Cynthia L. Flowers | Director | 2024-06-13 | A | 10,000 | 0 | 0 | RSU | Form 4 ↗ |
| Alicia Secor | Director | 2024-06-13 | A | 10,000 | 0 | 0 | RSU | Form 4 ↗ |
| Cynthia L. Flowers | Director | 2024-06-13 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-07-01 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Monica R. Thomas | Chief Legal & People Officer | 2024-07-01 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-07-01 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-07-01 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Perry | Chief Commercial Officer | 2024-07-01 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-07-01 | A | 105,000 | 0 | 0 | Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-07-05 | D | 7,662 | 3 | 19,214 | Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-07-05 | D | 2,475 | 3 | 6,207 | Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-07-05 | D | 2,475 | 3 | 6,207 | Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-07-05 | D | 2,638 | 3 | 6,615 | Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-07-05 | D | 527 | 3 | 1,322 | Common | Form 4 ↗ |
| Andrew Perry | Chief Commercial Officer | 2024-07-05 | D | 1,337 | 3 | 3,353 | Common | Form 4 ↗ |
| Alicia Secor | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alicia Secor | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alicia Secor | Director | 2024-09-18 | D | 10,000 | — | — | Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-09-18 | D | 161,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-09-18 | D | 201,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-09-18 | D | 196,287 | — | — | Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-09-18 | D | 534,787 | — | — | Common | Form 4 ↗ |
| Jacks Lee | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jacks Lee | Director | 2024-09-18 | D | 10,000 | — | — | Common | Form 4 ↗ |
| Jacks Lee | Director | 2024-09-18 | D | 10,000 | — | — | Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-09-18 | D | 74,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-09-18 | D | 21,150 | — | — | Common | Form 4 ↗ |
| Cynthia L. Flowers | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-09-18 | D | 26,035 | — | — | Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-09-18 | D | 236,610 | — | — | Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-09-18 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-09-18 | D | 6,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-09-18 | D | 74,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-09-18 | D | 168,387 | — | — | Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-09-18 | D | 185,358 | — | — | Common | Form 4 ↗ |
| Cynthia L. Flowers | Director | 2024-09-18 | D | 20,000 | — | — | Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-09-18 | D | 36,924 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-09-18 | D | 35,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-09-18 | D | 74,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-09-18 | D | 89,762 | — | — | Common | Form 4 ↗ |
| Garry A. Nicholson | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry A. Nicholson | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry A. Nicholson | Director | 2024-09-18 | D | 14,389 | — | — | Common | Form 4 ↗ |
| Monica R. Thomas | Chief Legal & People Officer | 2024-09-18 | D | 6,674 | — | — | Common | Form 4 ↗ |
| Monica R. Thomas | Chief Legal & People Officer | 2024-09-18 | D | 138,151 | — | — | Common | Form 4 ↗ |
| Norman Sharpless | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Norman Sharpless | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Perry | Chief Commercial Officer | 2024-09-18 | D | 67,050 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Perry | Chief Commercial Officer | 2024-09-18 | D | 114,482 | — | — | Common | Form 4 ↗ |
| Andrew Perry | Chief Commercial Officer | 2024-09-18 | A | 16,100 | — | — | Common | Form 4 ↗ |
| Jacks Lee | Director | 2024-09-18 | D | 60,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jacks Lee | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-09-18 | D | 87,450 | — | — | Common | Form 4 ↗ |
| Garry A. Nicholson | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-09-18 | D | 41,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-09-18 | D | 89,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-09-18 | D | 20,000 | — | — | Common | Form 4 ↗ |
| Alicia Secor | Director | 2024-09-18 | D | 20,000 | — | — | Common | Form 4 ↗ |
| Mark Avagliano | Chief Business Officer | 2024-09-18 | A | 20,600 | — | — | Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-09-18 | A | 17,900 | — | — | Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-09-18 | A | 17,900 | — | — | Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-09-18 | D | 35,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Terry L. Murdock | Chief Operating Officer | 2024-09-18 | D | 124,762 | — | — | Common | Form 4 ↗ |
| Glenn P. Muir | Director | 2024-09-18 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Perry | Chief Commercial Officer | 2024-09-18 | D | 32,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Perry | Chief Commercial Officer | 2024-09-18 | D | 14,232 | — | — | Common | Form 4 ↗ |
| Norman Sharpless | Director | 2024-09-18 | D | 20,000 | — | — | Common | Form 4 ↗ |
| Rajesh Malik | Chief Medical Officer | 2024-09-18 | D | 57,333 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John W. Umstead V | Chief Financial Officer | 2024-09-18 | D | 19,331 | — | — | Common | Form 4 ↗ |
| Bailey John E. (Jack) Jr. | Director | 2024-09-18 | A | 181,400 | — | — | Common | Form 4 ↗ |
| Garry A. Nicholson | Director | 2024-09-18 | D | 20,000 | — | — | Common | Form 4 ↗ |
| Cynthia L. Flowers | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cynthia L. Flowers | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Cynthia L. Flowers | Director | 2024-09-18 | D | 15,889 | — | — | Common | Form 4 ↗ |
| Monica R. Thomas | Chief Legal & People Officer | 2024-09-18 | D | 150,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Monica R. Thomas | Chief Legal & People Officer | 2024-09-18 | D | 55,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Alicia Secor | Director | 2024-09-18 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (134 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Bailey. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 3,250,658. View filing ↗
- Section 01, Mark Avagliano. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 1,171,543. View filing ↗
- Section 01, Rajesh Malik. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 1,108,156. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2024-04-25. Section “CEO Pay Ratio”. As printed: 12 : 1. View filing ↗
- Section 08, Mark A. Velleca, M.D., Ph.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 233,750. View filing ↗
- Section 08, Garry A. Nicholson. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 195,354. View filing ↗
- Section 08, Glenn P. Muir. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 172,854. View filing ↗
- Section 08, Cynthia L. Flowers. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 162,854. View filing ↗
- Section 08, Jacks Lee. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 145,354. View filing ↗
- Section 08, Alicia Secor. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 142,854. View filing ↗
- Section 08, Norman E. Sharpless, M.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 135,354. View filing ↗
- Section 08, John E. Bailey Jr. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Andrew Perry 2024-05-13. Form 4, filed 2024-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-05-13. Form 4, filed 2024-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-05-13. Form 4, filed 2024-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-05-13. Form 4, filed 2024-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-05-13. Form 4, filed 2024-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-05-13. Form 4, filed 2024-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Monica R. Thomas 2024-05-23. Form 4, filed 2024-05-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacks Lee 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry A. Nicholson 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry A. Nicholson 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacks Lee 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alicia Secor 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Sharpless 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Sharpless 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia L. Flowers 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alicia Secor 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia L. Flowers 2024-06-13. Form 4, filed 2024-06-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Monica R. Thomas 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Perry 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-07-05. Form 4, filed 2024-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-07-05. Form 4, filed 2024-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-07-05. Form 4, filed 2024-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-07-05. Form 4, filed 2024-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-07-05. Form 4, filed 2024-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Perry 2024-07-05. Form 4, filed 2024-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alicia Secor 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alicia Secor 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alicia Secor 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacks Lee 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacks Lee 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacks Lee 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia L. Flowers 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia L. Flowers 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry A. Nicholson 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry A. Nicholson 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry A. Nicholson 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Monica R. Thomas 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Monica R. Thomas 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Sharpless 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Sharpless 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Perry 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Perry 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Perry 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacks Lee 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacks Lee 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry A. Nicholson 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alicia Secor 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Avagliano 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Terry L. Murdock 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn P. Muir 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Perry 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Perry 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norman Sharpless 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rajesh Malik 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Umstead V 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bailey John E. (Jack) Jr. 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry A. Nicholson 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia L. Flowers 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia L. Flowers 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia L. Flowers 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Monica R. Thomas 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Monica R. Thomas 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alicia Secor 2024-09-18. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 84% (votes for as printed: 16,706,545). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: 85.54% (votes for as printed: 14,070,123). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-24. Item 5.07 · say-on-pay result. As reported: 75.18% (votes for as printed: 11,555,526). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 446,250 + equity 169,800 + all other 200,000 = 816,050, summed across the director compensation table rows.
- TG Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. View filing ↗
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- Deciphera Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. View filing ↗
- ImmunoGen Inc., Section 10b CEO total. DEF 14A, filed 2023-04-26. CEO total compensation as printed in ImmunoGen Inc.'s own proxy. As printed: 5,422,421. View filing ↗
- Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- Y-mAbs Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-05-30. CEO total compensation as printed in Y-mAbs Therapeutics, Inc.'s own proxy. As printed: 4,557,590. View filing ↗
- UroGen Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in UroGen Pharma, Inc.'s own proxy. As printed: 4,310,624. View filing ↗
- Reata Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Reata Pharmaceuticals, Inc.'s own proxy. As printed: 3,553,953. View filing ↗
- Esperion Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. View filing ↗
- G1 Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in G1 Therapeutics's own proxy. As printed: 3,250,658. View filing ↗
- Aveo Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-04. CEO total compensation as printed in Aveo Pharmaceuticals, Inc.'s own proxy. As printed: 3,214,100. View filing ↗
- Karyopharm Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Iovance Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. View filing ↗
- Agenus Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus Inc.'s own proxy. As printed: 1,350,325. View filing ↗
- BeyondSpring Inc., Section 10b CEO total. 10-K, filed 2026-03-25. CEO total compensation as printed in BeyondSpring Inc.'s own proxy. As printed: 702,182. View filing ↗
- Section 10a, Y-mAbs Therapeutics, Inc. reciprocity. DEF 14A. Y-mAbs Therapeutics, Inc. names G1 Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Esperion Therapeutics, Inc. reciprocity. DEF 14A. Esperion Therapeutics, Inc. names G1 Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ImmunoGen Inc. reciprocity. DEF 14A. ImmunoGen Inc. names G1 Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗